New Drug Approvals

 

Imatinib
ImatinibCAS No:- [152459-95-5]IUPAC Name:- 4-[(4-Methyl-1-piperazinyl)methyl]-N-[4-methyl-3-[[4-(3-pyridinyl)-2-pyrimidinyl]amino]phenyl]benzamideM. P.:- 211-213 °CMW: 493.60
4-[(4-methylpiperazin-1-yl)methyl]-N-(4-methyl-3-{[4-(pyridin-3-yl)pyrimidin-2-yl]amino}phenyl)benzamideImatinib (originally STI571) is a drug used to treat certain cancers. It is marketed byNovartis as Gleevec (USA) or Glivec (Europe/Australia/Latin America) as its mesylatesalt, imatinib mesilate (INN).Imatinib is the first of a new class of drugs that act by specifically inhibiting a certainenzyme – a receptor tyrosine kinase – that is characteristic of a particular cancer cell, rather than non-specifically inhibiting and killing all rapidly dividing cells. Imatinib was a model for other targeted therapies that inhibited this class of enzymes.It is used in treating chronic myelogenous leukemia (CML), gastrointestinal stromal tumors(GISTs) and some other diseases. By 2011, Gleevec has been FDA approved to treat ten different cancers.In CML, the tyrosine kinase enzyme ABL in white blood cells is locked in its activated form. This causes the excessive proliferation and high white blood cell…

View original post 887 more words

Advertisements

Leave a Reply

Fill in your details below or click an icon to log in:

WordPress.com Logo

You are commenting using your WordPress.com account. Log Out / Change )

Twitter picture

You are commenting using your Twitter account. Log Out / Change )

Facebook photo

You are commenting using your Facebook account. Log Out / Change )

Google+ photo

You are commenting using your Google+ account. Log Out / Change )

Connecting to %s